Pay in 4 interest-free payments of $6.21 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
March 19 Product: Takedas Iclusig Indication: Philadelphia chromosome-positive acute lymphoblastic leukemia Takeda scored a frontline approval for its kinase inhibitor Iclusig on Tuesday
(34798964) Super-Refractory Status Epilepticus (SRSE) : Refractory to two antiseizure medications and general anesthesia treatment for 24 hours, or when seizures reemerge during an attempted anesthetic wean
Atraxia Law can help you file your case
A clear vial may indicate a preparation error, missing dye additive, or potential contamination
A direct interaction often refers to one medication chemically altering another, leading to increased toxicity, reduced efficacy, or dangerous side effects
Neeland IJ, Eliasson B, Kasai T et al (2020) The impact of empagliflozin on obstructive sleep apnea and cardiovascular and renal outcomes: an exploratory analysis of the EMPA-REG OUTCOME trial
US$ 29.90
US$ 22.11
US$ 27.87
US$ 23.10
US$ 23.95
